CN108042623A - 一种透明质酸钠妇科抗菌凝胶 - Google Patents
一种透明质酸钠妇科抗菌凝胶 Download PDFInfo
- Publication number
- CN108042623A CN108042623A CN201711372514.XA CN201711372514A CN108042623A CN 108042623 A CN108042623 A CN 108042623A CN 201711372514 A CN201711372514 A CN 201711372514A CN 108042623 A CN108042623 A CN 108042623A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- sodium hyaluronate
- antibiotic gel
- gynaecologic antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002385 Sodium hyaluronate Polymers 0.000 title claims abstract description 37
- 229940010747 sodium hyaluronate Drugs 0.000 title claims abstract description 37
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 36
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 87
- 241001145009 Sophora alopecuroides Species 0.000 claims abstract description 19
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 18
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 18
- 244000062241 Kaempferia galanga Species 0.000 claims abstract description 18
- 235000013421 Kaempferia galanga Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 17
- 229930195725 Mannitol Natural products 0.000 claims abstract description 17
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 17
- 229960001631 carbomer Drugs 0.000 claims abstract description 17
- 239000000594 mannitol Substances 0.000 claims abstract description 17
- 235000010355 mannitol Nutrition 0.000 claims abstract description 17
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 238000004945 emulsification Methods 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 9
- 241000588724 Escherichia coli Species 0.000 abstract description 6
- 241000222122 Candida albicans Species 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 241000588653 Neisseria Species 0.000 abstract description 4
- 229940095731 candida albicans Drugs 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 210000004877 mucosa Anatomy 0.000 abstract description 4
- 230000019522 cellular metabolic process Effects 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 6
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 4
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000008777 kaempferol Nutrition 0.000 description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- MMCQRJPAMIHLQX-ZOWXZIJZSA-N Sophoramine Chemical compound C1CC[C@H]2CN3C(=O)C=CC=C3[C@@H]3[C@H]2N1CCC3 MMCQRJPAMIHLQX-ZOWXZIJZSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940065181 bacillus anthracis Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- -1 compounds Sodium Hyaluronate Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- ZSBXGIUJOOQZMP-BHPKHCPMSA-N sophoridine Chemical compound C1CC[C@@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-BHPKHCPMSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- GOKHLKYATMBASR-UHFFFAOYSA-N 2-(4-methylcyclohexyl)propan-1-ol Chemical compound OCC(C)C1CCC(C)CC1 GOKHLKYATMBASR-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MMCQRJPAMIHLQX-UHFFFAOYSA-N Isosophoromine Natural products C1CCC2CN3C(=O)C=CC=C3C3C2N1CCC3 MMCQRJPAMIHLQX-UHFFFAOYSA-N 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- WUVYENIUARJBNM-ABHRYQDASA-N Lehmannine Natural products O=C1N2[C@H]([C@H]3[C@H]4N(CCC3)CCC[C@H]4C2)C=CC1 WUVYENIUARJBNM-ABHRYQDASA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 235000000365 Oenanthe javanica Nutrition 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 235000013559 Schnittsellerie Nutrition 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 1
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 1
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- LCXREBMNASQAOC-UHFFFAOYSA-N Worenine Chemical compound C1=C2C(C)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=CC2=C1OCO2 LCXREBMNASQAOC-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- SKOLRLSBMUGVOY-GBJTYRQASA-N aloperine Chemical compound C1=C2CCCN[C@H]2[C@H]2CN3CCCC[C@@H]3[C@@H]1C2 SKOLRLSBMUGVOY-GBJTYRQASA-N 0.000 description 1
- PCTYDEAPIWWHMV-UHFFFAOYSA-N aloperine Natural products C1CCN2CC3CC(CC4CCCNC34)C2C1 PCTYDEAPIWWHMV-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- WUVYENIUARJBNM-JLNYLFASSA-N lehmanine Chemical compound C1CC[C@H]2CN3C(=O)CC=C[C@@H]3[C@@H]3[C@H]2N1CCC3 WUVYENIUARJBNM-JLNYLFASSA-N 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- QMGGMESMCJCABO-UHFFFAOYSA-N n-oxysophocarpine Chemical compound C12C3CCC[N+]2([O-])CCCC1CN1C3CC=CC1=O QMGGMESMCJCABO-UHFFFAOYSA-N 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- USDOQCCMRDNVAH-KKUMJFAQSA-N β-cadinene Chemical compound C1C=C(C)C[C@H]2[C@H](C(C)C)CC=C(C)[C@@H]21 USDOQCCMRDNVAH-KKUMJFAQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种透明质酸钠妇科抗菌凝胶，包括透明质酸钠、黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、甘露醇、卡波姆、三乙醇胺和水。本发明提出的一种透明质酸钠妇科抗菌凝胶，多种功能性组份科学配伍，可提高细胞的新陈代谢，加速皮肤黏膜的修复；该凝胶中包含多种植物提取物，不仅具有抗菌功效还能够提高机体免疫力。经临床验证，本发明制得的抗菌凝胶能有效抑制大肠杆菌、白色念珠菌、金黄色葡萄球菌和淋球菌；在治疗妇科炎症中具有良好的效果，其有效率为95.8%。
Description
技术领域
本发明属于医药技术领域，具体涉及一种透明质酸钠妇科抗菌凝胶。
背景技术
人体表面覆盖的皮肤和粘膜是人体抵抗外部致病微生物侵袭的防线，女性阴道的生理结构特征决定其容易受到外源病毒和细菌的感染，以致很多妇女都患有不同程度的妇科阴道疾病。阴道炎，宫颈炎、附件炎等为妇科常见、多发疾病，直接影响女性的身心建康，甚至会导致出现过早的衰老。
目前，治疗妇科炎症的药物比较多，口服药物剂型经肠胃吸收、血液循环进入阴道部位并杀死细菌，起效时间慢，一般须长期服用才显疗效；此外治疗妇科炎症的抗菌药还有栓剂类、洗剂类、喷剂类等，但大多数药物会对生殖道环境、黏膜自身分泌功能产生破坏，从而导致生殖局部免疫力的下降，并致使致病菌产生抗药性和耐药性，最终炎症反复发作。为了解决上述问题，本发明将透明质酸钠与多种植物抗菌成分复配，对皮肤黏膜起到保护的作用。
透明质酸是一种多功能基质，是人体皮肤表皮及真皮的主要成分之一。透明质酸具有高黏度、可塑性、渗透性、独特的流变学特性以及良好的生物相容性，故在这样的组织中水分运输缓慢，从而起到调节水分分布的作用。这使得透明质酸对细胞间隙的蛋白质和代谢产物具有调节作用，同时也起到了润滑剂的显著作用。同时它在组织修复过程尤其是皮肤的创伤愈合过程中发挥重要做作用。
发明内容
基于背景技术存在的技术问题，本发明针对现有技术中存在的上述不足，提供一种透明质酸钠妇科抗菌凝胶，含多种植物抗菌成分，具有良好的抗菌效果且安全无副作用。
本发明提出的一种透明质酸钠妇科抗菌凝胶，包括按照重量份计的如下组份：透明质酸钠0.3-0.7份、黄连提取物1-5份、艾叶提取物6-12份、甘露醇2-7份、卡波姆0.5-1.5份、三乙醇胺0.4-0.8份、水50-80份。
优选地，还包括高良姜提取物2-6份。
优选地，还包括牡丹皮提取物2-6份。
优选地，还包括苦豆子提取物3-8份。
优选地，包括按照重量份计的如下组份：透明质酸钠0.5份、黄连提取物3份、艾叶提取物8份、高良姜提取物5份、牡丹皮提取物5份、苦豆子提取物6份、甘露醇5份、卡波姆0.8份、三乙醇胺0.6份、水70份。
一种透明质酸钠妇科抗菌凝胶的制备方法，其特征在于，方法步骤如下：
S1：将水加入均质乳化锅中升温到90-95℃，保温30min，加入甘露醇、卡波姆，搅拌溶解均匀后，降温至45-50℃；
S2：将黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、透明质酸钠加入乳化锅，搅拌溶解均匀后，降温至45-50℃；
S3：加入三乙醇胺，搅拌30min，至溶液完全均匀；即得。
本发明采用的植物提取物均为纳米级粉末，可提高其生物利用率；本发明提出的一种透明质酸钠妇科抗菌凝胶应用于妇科炎症疾病。
本发明中主要组分的作用：
透明质酸钠为透明质酸的钠盐形式，含有大、中、小不同分子量的透明质酸成分；大分子透明质酸在皮肤表面形成一层透气的薄膜，对于治疗部位进行敷贴。使皮肤光滑湿润的同时可杀灭细菌并阻隔外来灰尘与紫外线的侵入，保护皮肤免受侵害；中小分子透明质酸可携带药物迅速渗透皮肤，使水分进入细胞间歇，促进蛋白质结合，发挥正常的细胞代谢作用，加快细胞再生。
黄连提取物中含小檗碱、黄连碱、甲基黄连碱、掌叶防已碱、非洲防己碱等生物碱，尚含黄柏酮、黄柏内酯。体外试验证明，小檗碱对溶血性链球菌、脑膜炎球菌、肺炎双球菌、霍乱弧菌、炭疽杆菌以及金黄色葡萄球菌皆有较强的抑菌作用；对痢疾杆菌、白喉杆菌、枯草杆菌、绿色链球菌均有抑制作用；对肺炎杆菌、百日咳杆菌、鼠疫杆菌、布氏杆菌、破伤风杆菌、产气荚膜杆菌、结核杆菌等亦有效。
艾叶提取物中包括萜品烯醇-4、β-石竹烯、蒿醇、芳樟醇、樟脑、龙脑、桉油素、水芹烯、毕澄茄烯、侧柏醇等。艾叶在体外对炭疽杆菌、α-溶血链球菌、B-溶血链球菌、白喉杆菌、假白喉杆菌、肺类双球菌、金黄色葡萄球菌、柠檬色葡萄球菌、白色葡葡球菌、枯草杆菌等10种革兰氏阳性嗜气菌皆有抗菌作用。
高良姜提取液中含高良姜素、山奈素-4’-甲醚、高良姜素-3-甲醚、原儿茶酸、槲皮素、山奈酚、β-谷甾醇和胡萝卜苷。其中高良姜素、原儿茶酸、槲皮素和山奈酚均具有抗菌活性，原儿茶酸和槲皮素对革兰氏阳性菌(金黄色葡萄球菌、枯草芽孢杆菌)和革兰氏阴性菌(大肠杆菌、铜绿假单胞菌)均具有较强的抗菌活性；高良姜素和山奈酚对革兰氏阳性菌(金黄色葡萄球菌、枯草芽孢杆菌)具有较强抗菌活性。
牡丹皮提取液中含儿茶素、丹皮酚、没食子酸等，对金黄色葡萄糖球菌、大肠杆菌及绿脓杆菌均有较强的抑制作用和一定的杀灭作用。
苦豆子味极苦、性寒有毒，具有抗菌消炎、清热解毒、止痛杀虫等作用。苦豆子提取物中包括苦参碱、氧化苦参碱、槐果碱、氧化槐果碱、槐胺碱、槐定碱、莱曼碱、苦豆碱，苦豆子生物碱具抗病毒、抗炎及免疫抑制作用，苦参总碱能抑制多种病毒繁殖，增强免疫调节功能和免疫促进作用。
与现有技术相比，本发明具有的有益效果在于：
本发明提出的一种透明质酸钠妇科抗菌凝胶，多种功能性组份科学配伍，可提高细胞的新陈代谢，加速皮肤黏膜的修复；该凝胶中的透明质酸钠携带的抗菌成分可迅速渗透皮肤，保护黏膜细胞不受病原菌侵害，并快速修复皮肤组织，提高创口愈合再生能力；该凝胶中包含多种植物提取物，不仅具有抗菌功效还能够提高机体免疫力。经临床验证，本发明制得的抗菌凝胶能有效抑制大肠杆菌、白色念珠菌、金黄色葡萄球菌和淋球菌；在治疗妇科炎症中具有良好的效果，其有效率为95.8％。
具体实施方式
下面结合具体实施例对本发明作进一步解说。
实施例1
一种透明质酸钠妇科抗菌凝胶，包括按照重量份计的如下组份：透明质酸钠0.3份、黄连提取物1份、艾叶提取物6份、高良姜提取物2份、牡丹皮提取物2份、苦豆子提取物3份、甘露醇2份、卡波姆0.5份、三乙醇胺0.4份、水50份。
一种透明质酸钠妇科抗菌凝胶的制备方法，其特征在于，方法步骤如下：
S1：将水加入均质乳化锅中升温到90℃，保温30min，加入甘露醇、卡波姆，搅拌溶解均匀后，降温至45℃；
S2：将黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、透明质酸钠加入乳化锅，搅拌溶解均匀后，降温至45℃；
S3：加入三乙醇胺，搅拌30min，至溶液完全均匀；即得。
实施例2
一种透明质酸钠妇科抗菌凝胶，包括按照重量份计的如下组份：透明质酸钠0.7份、黄连提取物5份、艾叶提取物12份、高良姜提取物6份、牡丹皮提取物6份、苦豆子提取物8份、甘露醇7份、卡波姆1.5份、三乙醇胺0.8份、水80份。
一种透明质酸钠妇科抗菌凝胶的制备方法，其特征在于，方法步骤如下：
S1：将水加入均质乳化锅中升温到95℃，保温30min，加入甘露醇、卡波姆，搅拌溶解均匀后，降温至50℃；
S2：将黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、透明质酸钠加入乳化锅，搅拌溶解均匀后，降温至50℃；
S3：加入三乙醇胺，搅拌30min，至溶液完全均匀；即得。
实施例3
一种透明质酸钠妇科抗菌凝胶，包括按照重量份计的如下组份：透明质酸钠0.5份、黄连提取物3份、艾叶提取物8份、高良姜提取物5份、牡丹皮提取物5份、苦豆子提取物6份、甘露醇5份、卡波姆0.8份、三乙醇胺0.6份、水70份。
一种透明质酸钠妇科抗菌凝胶的制备方法，其特征在于，方法步骤如下：
S1：将水加入均质乳化锅中升温到93℃，保温30min，加入甘露醇、卡波姆，搅拌溶解均匀后，降温至47℃；
S2：将黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、透明质酸钠加入乳化锅，搅拌溶解均匀后，降温至48℃；
S3：加入三乙醇胺，搅拌30min，至溶液完全均匀；即得。
实施例4
一种透明质酸钠妇科抗菌凝胶，包括按照重量份计的如下组份：透明质酸钠0.6份、黄连提取物2份、艾叶提取物10份、高良姜提取物4份、牡丹皮提取物3份、苦豆子提取物5份、甘露醇4份、卡波姆1.0份、三乙醇胺0.7份、水60份。
一种透明质酸钠妇科抗菌凝胶的制备方法，其特征在于，方法步骤如下：
S1：将水加入均质乳化锅中升温到91℃，保温30min，加入甘露醇、卡波姆，搅拌溶解均匀后，降温至46℃；
S2：将黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、透明质酸钠加入乳化锅，搅拌溶解均匀后，降温至49℃；
S3：加入三乙醇胺，搅拌30min，至溶液完全均匀；即得。
实施例5
一种透明质酸钠妇科抗菌凝胶，包括按照重量份计的如下组份：透明质酸钠0.4份、黄连提取物4份、艾叶提取物11份、高良姜提取物3份、牡丹皮提取物4份、苦豆子提取物7份、甘露醇6份、卡波姆1.2份、三乙醇胺0.5份、水75份。
一种透明质酸钠妇科抗菌凝胶的制备方法，其特征在于，方法步骤如下：
S1：将水加入均质乳化锅中升温到95℃，保温30min，加入甘露醇、卡波姆，搅拌溶解均匀后，降温至45℃；
S2：将黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、透明质酸钠加入乳化锅，搅拌溶解均匀后，降温至50℃；
S3：加入三乙醇胺，搅拌30min，至溶液完全均匀；即得。
产品性能测试
一、灭菌试验
1、实验方法：选用本发明实施例3制得的抗菌凝胶对大肠杆菌、金黄色葡萄球菌、白色念珠菌、淋球菌在不同作用时间下的杀菌率。灭菌率及试验所用试剂参照《消毒技术规范》(2002年版)，试验重复3次。
2、检测结果：见表1。
表1 抑菌测试结果
结论：由表1可见，本发明制得的抗菌剂对将大肠杆菌、白色念珠菌、金黄色葡萄球菌和淋球菌具有显著的抑制作用。
二、临床试验
1、试验对象：对95例阴道炎患者采用随机分组。
2、年龄：95例患者中最小年龄21岁，最大年龄42岁。
3、病程分布：95病例中：最短3个月，最长23个月。
4、观察与治疗方法：本发明制得的抗菌凝胶，每日1次，使用前清洗阴部，取本品一支，除去推进器盖帽，将推进器放入阴道内(3-5cm深处)，将液体一次性注入引到深处，取出推进器弃之，使用3个星期后复诊。
5、判断标准：
(1)显效：炎症消失，阴道清洁度为I度。
(2)有效：症状减轻，阴道清洁度为II度。
(3)无效，使用后无明显变化。
6、治疗结果：见表2。
表2 治疗结果
| 组别 | 人数 | 显效 | 有效 | 无效 | 总有效率 |
| 阴道炎 | 95 | 36 | 55 | 4 | 95.8％ |
表2表明：在95例试用患者中，有效者为91例，有效率为95.8％。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
Claims (7)
1.一种透明质酸钠妇科抗菌凝胶，其特征在于，包括按照重量份计的如下组份：透明质酸钠0.3-0.7份、黄连提取物1-5份、艾叶提取物6-12份、甘露醇2-7份、卡波姆0.5-1.5份、三乙醇胺0.4-0.8份、水50-80份。
2.根据权利要求1所述的一种透明质酸钠妇科抗菌凝胶，其特征在于，还包括高良姜提取物2-6份。
3.根据权利要求2所述的一种透明质酸钠妇科抗菌凝胶，其特征在于，还包括牡丹皮提取物2-6份。
4.根据权利要求3所述的一种透明质酸钠妇科抗菌凝胶，其特征在于，还包括苦豆子提取物3-8份。
5.根据权利要求1-4任一项所述的一种透明质酸钠妇科抗菌凝胶，其特征在于，包括按照重量份计的如下组份：透明质酸钠0.5份、黄连提取物3份、艾叶提取物8份、高良姜提取物5份、牡丹皮提取物5份、苦豆子提取物6份、甘露醇5份、卡波姆0.8份、三乙醇胺0.6份、水70份。
6.根据权利要求5所述的一种透明质酸钠妇科抗菌凝胶的制备方法，其特征在于，方法步骤如下：
S1：将水加入均质乳化锅中升温到90-95℃，保温30min，加入甘露醇、卡波姆，搅拌溶解均匀后，降温至45-50℃；
S2：将黄连提取物、艾叶提取物、高良姜提取物、牡丹皮提取物、苦豆子提取物、透明质酸钠加入乳化锅，搅拌溶解均匀后，降温至45-50℃；
S3：加入三乙醇胺，搅拌30min，至溶液完全均匀；即得。
7.权利要求1-4任一项所述的妇科抗菌凝胶应用于妇科炎症疾病。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711372514.XA CN108042623A (zh) | 2017-12-19 | 2017-12-19 | 一种透明质酸钠妇科抗菌凝胶 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711372514.XA CN108042623A (zh) | 2017-12-19 | 2017-12-19 | 一种透明质酸钠妇科抗菌凝胶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108042623A true CN108042623A (zh) | 2018-05-18 |
Family
ID=62133866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711372514.XA Pending CN108042623A (zh) | 2017-12-19 | 2017-12-19 | 一种透明质酸钠妇科抗菌凝胶 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108042623A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109793706A (zh) * | 2019-03-20 | 2019-05-24 | 吉林省盛赛医药实业有限公司 | 一种运用羧基双离子生物交联技术的妇科凝胶及其制备方法 |
| CN110327286A (zh) * | 2019-07-29 | 2019-10-15 | 江苏迦南美地生物科技有限公司 | 一种含有苦豆子总碱成分的妇科用抑菌避孕凝胶 |
| CN114404359A (zh) * | 2022-01-28 | 2022-04-29 | 湖南伟方生命科技有限公司 | 一种妇科美白滋润护理凝胶及其制备方法 |
| CN115501328A (zh) * | 2022-08-30 | 2022-12-23 | 陕西东健药业有限公司 | 一种薁磺酸钠壳聚糖凝胶及其制备工艺 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660130A (zh) * | 2004-12-20 | 2005-08-31 | 凌沛学 | 含海藻糖和透明质酸的人体润滑剂及其制备方法 |
-
2017
- 2017-12-19 CN CN201711372514.XA patent/CN108042623A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660130A (zh) * | 2004-12-20 | 2005-08-31 | 凌沛学 | 含海藻糖和透明质酸的人体润滑剂及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| MURAT EKIN ET.AL: "The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial", 《 ARCHIVES OF GYNECOLOGY & OBSTETRICS》 * |
| 宫毓静等: "牡丹皮等10种中药对白色念珠菌浮游菌和生物膜作用的研究", 《中国实验方剂学杂志》 * |
| 张云玲: "探究"阿是祛痒洗剂"熏浸治疗糖尿病念珠菌性阴道炎的安全性", 《糖尿病新世界》 * |
| 高学敏等: "《临床中药学》", 31 January 2006, 河北科学技术出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109793706A (zh) * | 2019-03-20 | 2019-05-24 | 吉林省盛赛医药实业有限公司 | 一种运用羧基双离子生物交联技术的妇科凝胶及其制备方法 |
| CN110327286A (zh) * | 2019-07-29 | 2019-10-15 | 江苏迦南美地生物科技有限公司 | 一种含有苦豆子总碱成分的妇科用抑菌避孕凝胶 |
| CN114404359A (zh) * | 2022-01-28 | 2022-04-29 | 湖南伟方生命科技有限公司 | 一种妇科美白滋润护理凝胶及其制备方法 |
| CN114404359B (zh) * | 2022-01-28 | 2024-04-02 | 湖南伟方生命科技有限公司 | 一种妇科美白滋润护理凝胶及其制备方法 |
| CN115501328A (zh) * | 2022-08-30 | 2022-12-23 | 陕西东健药业有限公司 | 一种薁磺酸钠壳聚糖凝胶及其制备工艺 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108452295A (zh) | 一种抑菌、调节微生态平衡的紧致凝胶及制备方法 | |
| CN108042623A (zh) | 一种透明质酸钠妇科抗菌凝胶 | |
| CN113413375A (zh) | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 | |
| CN102058781A (zh) | 用于治疗烧烫伤的中药膜剂 | |
| CN104043098A (zh) | 一种用于治疗妇女阴道炎的抗菌肽冻干制剂及制备方法 | |
| CN111973551A (zh) | 一种贻贝粘蛋白抑菌凝胶及其制备方法 | |
| US7790928B1 (en) | Therapeutic dimethyl sulfoxide (aka DMSO) compositions and methods of use | |
| CN110664858B (zh) | 一种用于皮肤的青蒿提取物组合物、产品及其应用 | |
| CN104474536A (zh) | 仙鹤草鲜药治疗创伤伤口制剂 | |
| Salmah et al. | Synergistic effects of alcoholic extract of sweet basil (Ocimum basilicum L.) leaves and honey on cutaneous wound healing in rats | |
| HK1045813A1 (zh) | 局部敷用的含甘油及斗篷草精華的非固體合成劑 | |
| CN101757119B (zh) | 一种治疗阴道炎的药物组合物、凝胶剂及其制备方法 | |
| WO2018161890A1 (zh) | 小檗碱在制备治疗急性软组织损伤的药物中的应用 | |
| CN103251691A (zh) | 治疗奶牛乳房炎的中药方剂及其提取物和制剂 | |
| CN113813308A (zh) | 一种治疗烧烫伤的药物及其制备方法 | |
| CN100427118C (zh) | 一种烧烫伤药 | |
| CN113230390A (zh) | 一种组合物、阴道洗剂及其在妇科黏膜损伤修复中的应用 | |
| CN112206281A (zh) | 一种抗感染修复创面的药物组合物及其制备方法与应用 | |
| CN1175850C (zh) | 一种治疗烧、烫伤的药物及其制作方法 | |
| CN105560763A (zh) | 中药组合物皮肤消毒液 | |
| CN105497460A (zh) | 一种用于皮肤消毒的消毒液 | |
| CN1104247C (zh) | 一种治疗宫颈糜烂、阴道炎的栓剂 | |
| RU2173155C1 (ru) | Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат | |
| CN105395527A (zh) | 一种海洋生物护伤喷膜剂的制备方法 | |
| CN107952022A (zh) | 一种银离子妇科抗菌凝胶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180518 |